Development of epigenetic-based therapies for PDAC
(P13)
Subject Area
Gastroenterology
Term
from 2018 to 2023
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 329628492
The epigenetic machinery is contributing to multiple aspects of the disease ranging from tumor initiation to metastasis and therapy resistance. Drugs targeting the epigenetic machinery have entered clinical testing. Our data show that the histone deacetylase inhibitor Panobinostat is highly efficient in an aggressive subtype of the disease. Therefore, we aim to comprehensively understand Panobinostat sensitivity and will develop mechanism-based Panobinostat-anchored combination therapies. In addition, we aim to systematically decipher the contribution of epigenetic mechanisms to therapy resistance, which is a major clinical problem.
DFG Programme
Collaborative Research Centres
